Regeneron Pharma (REGN) PT Raised to $925 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron (REGN) gets its 'mojo back' after FDA approves Eylea HD
August 21, 2023 8:02 AM EDTShares of Regeneron (NASDAQ: REGN) gained over 1% in pre-open trading Monday after the FDA on Friday approved EYLEA HD Injection 8 mg for the treatment of patients with wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The approval process for EYLEA HD had been awaiting resolution since the unexpected Complete Response Letter (CRL) issued by the FDA in late June and prompted several Wall Street analysts to raise their price targets.
Following the approval, individuals diagnosed with wet age-related macular degeneration or diabetic retinal disease can now undergo fewer injections after their initial... More
Regeneron Pharma (REGN) PT Raised to $1,050 at Oppenheimer
August 21, 2023 6:16 AM EDTOppenheimer analyst Hartaj Singh raised the price target on Regeneron Pharma (NASDAQ: REGN) to $1,050.00 (from $950.00) while maintaining a Outperform rating.
The analyst commented, "Regeneron (REGN) announced late on 8/18 that Eylea High Dose (HD, aflibercept 8mg injection) was approved by the FDA for the... More
Regeneron Pharma (REGN) PT Raised to $985 at BMO Capital
August 21, 2023 6:10 AM EDTBMO Capital analyst Evan David Seigerman raised the price target on Regeneron Pharma (NASDAQ: REGN) to $985.00 (from $960.00) while maintaining a Outperform rating.
The analyst commented, "Eylea HD approval in wAMD, DME, and DR comes earlier than expected after Catelent fill and finish CRL... More
